You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Baseline clinical characteristics of the participants, dead vs alive in the follow-up

From: Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study

  All HIV n = 369 Dead N = 62 Alive N = 307 Univariate p
Age, years 43.0 ± 9 46.4 ± 8 42.3 ± 9 0.001
Male, n (%) 232 (62.9) 44 (71.0) 188 (61.2) 0.148
Body mass index, kg × m−2 24.2 ± 4 24.0 ± 4 24.2 ± 4 0.718
IDU risk factor, n (%) 101 (27.4) 30 (48.4) 71 (23.1) <0.001
Cigarette smoking, n (%) 199 (53.9) 40 (64.5) 159 (51.8) 0.067
Systolic blood pressure, mm Hg 130.5 ± 17 130.7 ± 20 130 ± 16 0.91
Total cholesterol, mg/dL 181 ± 48 170 ± 47 183 ± 47 0.052
High-density lipoprotein cholesterol, mg/dL 55 ± 20 49 ± 22 56 ± 19 0.218
Diabetes, n (%) 27 (7.3) 6 (9.1) 21 (6.8) 0.434
CDC stage C3, n (%) 105 (28.5) 32 (51.6) 73 (23.8) <0.001
Baseline CD4 lymphocyte mm3 501 ± 309 393 ± 331 523 ± 300 0.005
Baseline HIV-RNA < 50 copies/mL, n (%) 256 (69.4) 41 (46.1) 215 (70.0) 0.543
Nadir CD4 lymphocyte mm3 181 ± 158 141 ± 130 189 ± 162 0.012
Zenit HIV-RNA, copies/mL (log10) 5.0 ± 0.8 5.0 ± 0.6 5.0 ± 0.8 0.620
Hepatitis C infection, n (%) 111 (30.2) 29 (46.8) 82 (26.8) 0.002
  1. Values are mean ± SD
  2. CVD cardiovascular disease, SCORE systematic coronary risk evalutation, CDC Centers for Disease Control and Prevention, IDU injecting drug user